Radioimmunotherapy with 90Y-ibritumomab tiuxetan is a safe and efficient treatment for patients with B-cell lymphoma relapsed after auto-SCT: An analysis of the international RIT-Network

Bone Marrow Transplantation

Volumn 46, Issue 6, 2011, Pages 901-903

  Hohloch, K ^a   Zinzani, P L ^b   Linkesch, W ^c   Jurczak, W ^d   Deptala, A ^e   Lorsbach, M ^f   Windemuth Kiesselbach, C ^f   Wulf, G G ^a   Truemper, L H ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d JAGIELLONIAN UNIVERSITY   (Poland)

^e Central Hospital   (Poland)

^f ALCEDIS GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IBRITUMOMAB TIUXETAN;

ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BLOOD TOXICITY; CANCER REGISTRY; CANCER RELAPSE; CANCER STAGING; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; LARGE CELL LYMPHOMA; LETTER; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; DATA COLLECTION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; RADIOIMMUNOTHERAPY; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT; YTTRIUM RADIOISOTOPES;

EID: 79958133177     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.202     Document Type: Letter

References (8)

1. Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002; 99: 4336-4342. (Pubitemid 34627198)
2. + B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3793-3803.
3. Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN et al. White treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002; 2: 3262-3269. (Pubitemid 34831524)
4. 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000; 96: 1259-1266.
5. Vose JM, Bierman PJ, Enke C, Hankins J, Bociek G, Lynch JC et al. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 461-467. (Pubitemid 46224222)
6. Vose JM, Biermann PJ, Loberiza FR, Bociek RG, Matso D, Armitage JO. Phase I trial of 90Y-ibritumnumyb tiutexan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation. Leuk Lymphoma 2007; 48: 683-690. (Pubitemid 46605539)
7. Molina A, Krishnan A, Fung H, Flinn IW, Inwards D, Winter J et al. Use of radioimmunotherapy in stem cell transplantation and posttransplantation: focus on yttrium 90 ibritumomab tiutexan. Curr Stem Cell Res Ther 2008; 2: 239-248.
8. Jacobs SA, Vidnovic N, Joyce J, McCook B, Torok F, Avril N. Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy. Clin Cancer Res 2005; 11: 7146s-7150s.